Related references
Note: Only part of the references are listed.Cyclin D3 action in androgen receptor regulation and prostate cancer
N. A. Olshavsky et al.
ONCOGENE (2008)
Enhancing the anti-angiogenic action of histone deacetylase inhibitors
Selena Kuljaca et al.
MOLECULAR CANCER (2007)
Expression and prognostic significance of cyclin D3 in ovarian adenocarcinomas
Georgia Levidou et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo
Dexuan Gao et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2007)
Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells InVitro and InVivo
Shabana Shabbeer et al.
PROSTATE (2007)
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
R. A. Blaheta et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis
P. Rojas et al.
ONCOGENE (2007)
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma
Qiwei Yang et al.
CANCER RESEARCH (2007)
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells
Alessandra Valentini et al.
CANCER BIOLOGY & THERAPY (2007)
Sinusoidal swinging dynamics of the telomere repair and cell growth activation functions of telomerase in rat liver cancer cells
Claire Wolfrom et al.
FEBS LETTERS (2007)
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells
David Yu Greenblatt et al.
ONCOLOGIST (2007)
Loss of p27((Kip1)) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer
Ambrosi Pertia et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2007)
Adjuvant therapy for renal cell carcinoma
Kenneth M. Jacobsohn et al.
SEMINARS IN ONCOLOGY (2006)
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
David Z. Qian et al.
CANCER RESEARCH (2006)
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo
Qinghua Xia et al.
CANCER RESEARCH (2006)
Epidemiology of kidney cancer
A Rubagotti et al.
EUROPEAN UROLOGY SUPPLEMENTS (2006)
RNA interference suppression of MUC1 reduces the growth rate and metastatic phenotype of human pancreatic cancer cells
Hideaki Tsutsumida et al.
CLINICAL CANCER RESEARCH (2006)
Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity
J Tan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies
RA Blaheta et al.
MEDICINAL RESEARCH REVIEWS (2005)
Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells
WD Beecken et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer
R Kuefer et al.
BRITISH JOURNAL OF CANCER (2004)
Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique
C Langner et al.
VIRCHOWS ARCHIV (2004)
Cyclin E and P27 protein content in human renal cell carcinoma: Clinical outcome and associations with cyclin D
Y Hedberg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase
CL Bacon et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters
Y Hedberg et al.
ACTA ONCOLOGICA (2002)
Systemic therapy for renal cell carcinoma
RJ Motzer et al.
JOURNAL OF UROLOGY (2000)
Share Paper
